Vaccine Research
Vaccine Research
vacres
Medical Sciences
http://vacres.pasteur.ac.ir
1
admin
2383-2819
2423-4923
10.61186/vacres
en
jalali
1398
9
1
gregorian
2019
12
1
6
2
online
1
fulltext
en
Assessment of PhtD C-Terminal Immunogenicity by Opsonophagocytosis Assay (OPA) with OMVs as Adjuvants
Vaccine development, efficacy and safety evaluation
Vaccine development, efficacy and safety evaluation
پژوهشي
Research
<strong>Introduction:</strong> <em>Streptococcus pneumoniae</em> causes invasive and non-invasive diseases in children and adults. Currently, there are two types of pneumococcal vaccines: 23-valent pneumococcal polysaccharide vaccine and 13-valent pneumococcal conjugate vaccine which have caused many failures. Therefore, a new generation of pneumococcal vaccines is being pursued. <strong>Methods:</strong> An improved version of our previous study was performed using recombinant C-terminal of pneumococcal polyhistidine triad protein D (PhtD-C) as a vaccine antigen. The antigen was combined with meningococcal outer membrane vesicle (OMV) and alum as adjuvants to immunize BALB/c mice intraperitoneally. The generated total IgG, specific IgG, IgG1 and IgG2a antibodies and the killing ability of pneumococci by an opsonophagocytosis assay were then assayed. <strong>Results:</strong> Immunization by 30 µg PhtD-C and 50 µg OMV as an adjuvant, induced higher amounts of functional antibodies compared to our previous study while killing 50-55% of pneumococci cells. <strong>Conclusion:</strong> At optimized concentrations, PhtD-C and meningococcal OMV could be considered as a potent immunogens and the induced specific IgGs were effective and functional for killing pneumococci.
Streptococcus pneumonia, Meningococcal OMV, PhtD, Adjuvant
37
41
http://vacres.pasteur.ac.ir/browse.php?a_code=A-10-926-1&slc_lang=en&sid=1
Mohammadali
Malekan